Back to Headlines
Health
May 10, 2026
Analyzed by GPT OSS 120B

FDA Blocks Publication of Vaccine Safety Studies, HHS Official Says

AI Summary
The U.S. Food and Drug Administration has prevented the release of multiple studies that found Covid‑19 and shingles vaccines to be safe, according to HHS spokesperson Andrew Nixon. The action fuels debate over regulatory transparency, political influence, and the future of vaccine policy in the United States.

The Lead: FDA’s Intervention in Vaccine Safety Research

The U.S. Food and Drug Administration has blocked the publication of several government‑funded studies that concluded Covid‑19 and shingles vaccines are safe, a move confirmed by Andrew Nixon, spokesperson for the Department of Health and Human Services.

FDA Halts Publication of Covid‑19 and Shingles Vaccine Safety Studies

Agency scientists analyzed millions of patient records and reported that serious side‑effects were rare. Despite peer‑review acceptance, the studies were withdrawn after the FDA cited “methodological rationales” and a need to protect the agency’s scientific integrity.

  • Study 1: Reviewed 7.5 million Medicare beneficiaries aged 65+ (2023‑2024).
  • Study 2: Covered 4.2 million individuals aged 6 months‑64 years.
  • Two additional Shingrix studies were stopped from abstract submission in February.

Study Findings on Rare Adverse Events

Both Covid‑19 studies examined 14 potential outcomes, including heart attacks, strokes, Guillain‑Barré syndrome, fever‑related seizures, and myocarditis. The only statistically notable signal was anaphylaxis, occurring at roughly 1 in 1 million Pfizer vaccine recipients. No other significant risk elevations were observed.

Implications for Public Trust and Vaccine Policy

The withdrawals have sparked criticism from legal scholars such as Dorit Reiss and former FDA official Janet Woodcock, who argue the pattern undermines confidence in vaccine safety data. The episode occurs amid heightened scrutiny of HHS leadership under Robert F Kennedy Jr. and internal tensions reported at the FDA under Commissioner Marty Makary.

Future Oversight and Potential Policy Shifts

Analysts predict increased congressional hearings and possible legislative mandates for greater transparency in FDA‑sponsored research. If the agency continues to withhold safety data, biotech firms may face mounting pressure to seek alternative review pathways, potentially reshaping the U.S. vaccine approval landscape.